“Heat Engine” May Link Growing Pipeline of Targets At Crystal Lake’s Newmont Lake Project
Momentum Public Relations
Press Release: February 12, 2019
Crystal Lake Mining Corporation (TSXV: CLM, the “Company” or “CrystalLake“) is pleased to provide an update on the latest understanding of the mineral system model for the variety of occurrences and exploration targets within the 430 sq. km Newmont Lake Project along the western flank of the Eskay Rift – one of the largest land packages in this prolific district.
- Ongoing reinterpretation by Crystal Lake’s technical team of historical and recent released data indicate the potential for a linkage between the historic Northwest gold zone, the Ken-Glacier-O’Neill mineral zone (KGO) approximately 3 km to the north, and other adjacent occurrences along this trend. These exploration targets show potential to host high-grade systems and may be genetically linked to a cluster of granitoid intrusions that comprise part of a “Heat Engine” along the Newmont Lake Graben structure in the heart of the property;
- Within this geological framework, Crystal Lake has a focus on the discovery of mineral deposit types including but not limited to high-grade gold, copper-gold porphyry, skarn and volcanogenic massive sulphide types;
- A total of 22 separate mineral occurrences have been outlined historically across the project area. Rapidly receding snowfields, advances in technology, and a much greater understanding of the regional geology leads the Crystal Lake team to believe that the Newmont Lake Project will emerge as a “jewel” of the Golden Triangle in 2019;
- Crystal Lake looks forward to providing a series of updates including more results from last fall’s programs, notably from the Company’s first drilling at Burgundy Ridge and the Northwest zone, as the month progresses.
Dr. Peter Lightfoot, Technical Advisor for Crystal Lake who was part of the team responsible for the discovery of the Golden Triangle’s first nickel-copper-rich massive sulphide system less than 15 km from the southern border of the Newmont Lake Project, commented: “There are vast tracts of unexplored and under-explored ground within the Newmont Lake Project to feed an already large pipeline of quality targets rarely seen on one property. Our mission is to focus on the targets we interpret to have the highest immediate potential. This has me and our discovery team extremely excited for 2019.”
Crystal Lake has an option to earn a 100% interest in the Newmont Lake Project from Romios Gold Resources (TSXV: RG) – refer to September 24, 2018, and December 3, 2018, news releases.
Qualified Person
The technical information in this news release has been reviewed and approved by Dr. Peter C. Lightfoot, P.Geo., a Qualified Person responsible for the scientific and technical information in this news release under National Instrument 43-101 standards.
About Crystal Lake Mining
Crystal Lake Mining is a Canadian-based junior exploration company focused on building shareholder value through high-grade discovery opportunities in British Columbia and Ontario. The Company has an option to earn a 100% interest in the Newmont Lake Project, one of the largest land packages among juniors in the broader Eskay region in the heart of Northwest B.C.’s Golden Triangle.
On behalf of The Board of Directors of Crystal Lake Mining Corporation
Richard Savage, President & CEO
This news release may contain certain “forward looking statements”. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Any forward-looking statement speaks only as of the date of this news release and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Crystal Lake Mining Corporation
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2019/12/c1942.html
- Published in Business, Crystal Lake Mining, Mining, News Home
Tetra Bio-Pharma Provides Update on its Neuropathic and Chronic Pain Drug Development Program
Momentum Public Relations
Press Release: February 12, 2019
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, today announced accelerated development of its second-generation drug inhalation program for fibromyalgia and uncontrolled pain over the last months.
A Phase 1 study in healthy volunteers using vaporized PPP001 was successfully completed (click here) and the Corporation filed a patent application after unexpectedly discovering the unique composition of cannabis smoke. In July 2018, the Corporation entered into a co-development agreement with Storz & Bickel, widely recognized as the global leader in vaporizer design and manufacturing. Tetra incorporated the vaporizer into its smoke-vapor research program as it aimed to understand how inhaled cannabis relieves pain for patients.
About Neuropathic Pain (Fibromyalgia) and Chronic Pain
Fibromyalgia affects about 4 million U.S. adults or about 2% of the adult populationi. The main symptom associated with the condition is the wide range of pain symptoms that can be deep, sharp, dull, throbbing, or aching, affecting the muscles, tendons, and ligaments around the joints throughout the entire body. Treatments aimed at pain relief are the primary treatment intervention including an increasing use of opioids. Chronic pain is also associated with numerous other medical conditions including rheumatoid arthritis, osteoarthritis, gastro intestinal problems, cancer, surgery, HIV/AIDS. The global fibromyalgia treatment market was valued at approximately $10 billion dollars in 2017ii.
Tetra gained knowledge and understanding as to how smoked and vaporized cannabis works to relieve pain, based on its double-blind randomized placebo-controlled studies of PPP001 administered with the titanium pipe and Mighty Medic vaporizer and the use of smoke-vapor trapping studies to quantify exposure to the respiratory tract. A significant finding of the study was learning how much of each cannabinoid and terpene is delivered to the human body as the result of smoking or vaporizing a dried cannabis product. The key to the success of a smoked cannabis product is closely linked to its speed of delivery to the brain. In addition, the inhalation mode of delivery results in significantly higher maximal plasma levels at the peak of treatment. What does this mean? Essentially, results from our study in humans showed that the peak therapeutic levels show only a 1-minute difference in delivery between the pipe and vaporizer. Combined with the speed, the levels of cannabinoids delivered at this peak of exposure are what results in the benefits seen in patients who suffer from pain.
The pipe or vaporizer delivered important differences in some cannabinoids and terpenes. Tetra is using this insight to accelerate the development of alternative formulations for the treatment of fibromyalgia and uncontrolled chronic pain. This knowledge is incorporated in the filed patent application and based on this, Tetra will use isolates or synthetic-based supplies of cannabinoids and terpenes to develop these prescription cannabinoid-derived medicines.
During the last quarter of 2018, the Corporation began preparations for a research site in the United States to conduct its fibromyalgia clinical trial and we are intent on expanding clinical sites in Canada and in the USA in 2019.
“We previously communicated that after reviewing the human clinical data, Tetra anticipated proceeding into phase 2 clinical trials in fibromyalgia patients,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “We are committed to this target and plan to accelerate this development in the USA as well. Tetra has and continues to gain tremendous credibility within the medical community. We earned this credibility because of our clinical studies and exhaustive characterization of the pharmaceutical composition of cannabis-derived smoke and vaporization products. Overall, 2018 was a productive year after completing several clinical trials and we expect 2019 to build on this as we accelerate this program.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
- Published in Business, Medical Marijuana, News Home, Tetra Bio Pharma
Mondias Completes Characterization of CELEXT07 that Confirms Its Biostimulant and Antifungal Capabilities and Expands Its Global Market Potential
Momentum Public Relations
Press Release: February 12, 2019
Mondias Naturals Inc (“Mondias” or “NHP“), (TSXV: NHP), announces that the research collaboration with McGill University has led to the identification of CELEXT07 signatory metabolite compounds, antibiotic properties and functional roles in plant physiology. This will lead to the development of several commercial products to meet emerging needs in bio-agricultural and organic markets and offer new chemical free solutions for the cultivation and food storage industries.
The chemical classes of compounds identified in the CELEXT07 extract confirms the botanical agent’s properties associated with plant defense against biotic stress by boosting the plant’s resistance as well as a biostimulant effect on growth. The identification of these compounds supports the previous research demonstrating CELEXT07’s biostimulant and antifungal protective and treatment properties.
Mr. Jean-Philippe Gravel, CEO of Mondias Naturals stated, “These results validate Mondias’ strategy to develop natural products for agricultural markets including post-harvest sub-markets. The CELEXT07 botanical extract will make a significant contribution to the bio-agricultural and organic markets and allow growers to offer horticultural products grown with no chemical agents. We are excited by this advancement since CELEXT07 is an eco-friendly alternative to synthetic fungicides.”
Postharvest diseases caused by storage fungi are responsible for the estimated loss of about 20 to 25% of harvested fruits and vegetables, and will certainly affect Canada’s new cannabis industry. Some fungi may produce mycotoxins that can cause toxicity to both animals and humans. Mycotoxin contaminations can occur in the field and greenhouse, before and after harvest, and also during post-harvest activities and storage. Mondias has been developing its CELEXT07 products to help prevent fungal growth on plants through its proven ability to increase plants’ defense system.
As previously reported in its December 5, 2018 news release, CELEXT07, when used as a soil drench agent, significantly reduced lesions caused by fungi on two greenhouse growing plants, tomato and lettuce, and significantly reduced lesions on detached leaves. Mondias has been expanding its research activities to target food and crop storage. Mr. Jean-Philippe Gravel, CEO of Mondias Naturals stated, “These results suggest that CELEXT07 botanical extract may become a low-risk solution to the new Canadian and USA cannabis agricultural industries.”
The market potential for CELEXT07 is considerable considering that these infections result in annual economic losses between $10 billion to $100 billion worldwide (L. Hua et al. 2018) and that about one-third of the food produced worldwide for human consumption is lost after harvest (Gastavsson et al., 2011).
About Mondias Natural Products Inc. Mondias specializes in the commercialization and development of evidence based botanical products for the health care, bio agriculture and organic markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Business, Life Sciences, Mondias Natural, News Home, Technology
Mondias Announces an Amendment to its Stock Option Plan
Momentum Public Relations
Press Release: February 11, 2019
Mondias Natural Products Inc. (TSXV: NHP) (“Mondias” or the “Corporation”), a Corporation that specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets, announces that its Board of Directors has approved an amendment to its stock option plan to become effective upon approval by the shareholders of the Corporation at the Annual General Meeting of shareholders to be held later this year and upon receipt of final approval by the TSX Venture Exchange Inc. A copy of the proposed Stock Option Plan will be available from the Chief Executive Officer of the Corporation upon request and will be attached to the Information Circular to be filed on SEDAR, at www.sedar.com, for the upcoming Annual General Meeting of the shareholders.
The Corporation proposes to replace the fixed 20% stock option plan with a rolling 10% stock option plan. Under the rolling 10% stock option plan, the Corporation may grant options to acquire common shares of the Corporation equal to 10% of the issued and outstanding shares from time to time subject to the terms and conditions prescribed by the TSX Venture Exchange Inc. and applicable securities laws.
Currently outstanding options to purchase common shares of the Company granted prior to the amendment will continue to be exercisable and will be governed by and subject to the terms of the amended plan.
Based on the Company’s current issued and outstanding common share amount of 63,135,805, the amended rolling plan maximum is currently 6,313,581 common shares. Prior to the amendments to the plan, the fixed plan maximum was 400,408 common shares.
On January 22, 2019, the Board of Directors had approved the grant, subject to shareholder and regulatory approval, of incentive stock options under the amended 2019, 10% Rolling Stock Option Plan to the directors and officers of the Corporation for the purchase of a total of 2,550,000 shares in its capital. The options are exercisable before January 22, 2029, at the price of $0.235 per share (the closing price of the shares on January 21, 2019). The stock options vest over a 3-year period, with the first vesting period delayed until all regulatory and shareholder approvals are received.
About Mondias Natural Products Inc. Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit : mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Mondias Natural Products Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2019/11/c1683.html
Contact:
Jean Philippe Gravel, CEO, Telephone: 514-804-4569, Email : jpgravel@mondias.ca
- Published in Business, Life Sciences, Mondias Natural, News Home
CROP’s Washington Tenant Farm ‘Test Success’ With Nine Strains now Approved for Sale
Momentum Public Relations
Press Release: February 07, 2019
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today its Washington State tenant’s first crops have had successful test results.
The samples showed a range of Tetrahydrocannabolic Acid (‘THCA’) results and passed all tests for microbial impurities and no detectable pesticides. THCA is not directly used, but its presence is commonly analyzed when cannabis, or hemp-based products, are screened for THC. The tenant is now approved to begin selling the products in the Washington State market.
STRAIN |
THCA |
9 LB Hammer |
26.65% |
Woo |
19.47% |
Dutch Hawaiian |
22.54% |
Bubba Kush |
27.35% |
Gorilla Glue |
18.16% |
Green Crack |
17% |
Star Killer |
26.99% |
Ghost Train |
16.02% |
Dutch Treat (Distillate) |
79.1% THC 12.31% CBD |
The tenant is working with both bulk extraction buyers as well as retail locations under the Hempire and Evolution brands in the Washington market.
CROP CEO, Michael Yorke, stated: “This is an excellent result and certainly bodes well for the future. CROP’s tenant production teams continue to show what meticulous controls, defined production protocols and a focus on organic operations can mean in terms of resulting products.”
About CROP
CROP is publicly listed on the CSE and trades under the symbol “CROP”. CROP is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the California Project; the technological effects of California Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: +1(604) 484-4206
View original content:http://www.prnewswire.com/news-releases/crops-washington-tenant-farm-test-success-with-nine-strains-now-approved-for-sale-300791442.html
- Published in Business, CROP Infrastructure, hemp, Marijuana, News Home
Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067
Momentum Public Relations
Press Release: February 06, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona’s skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
The skincare company has completed extensive due diligence on TFC-1067. This includes both the data package provided by Sirona as well as their independent research and analysis on the compound. This work is contributing to the goal of an international commercial launch of what we are proving will be both a safe and effective skin lightener in an industry where other compounds typically suffer from either poor efficacy or toxicity issues.
The ROFR agreement, which includes all territories except China, states that upon receipt of the clinical trial report from dermatologist Dr. Zoe Draelos, the company will have 30 days to review the data. At that time, the company will notify Sirona of their intent to conclude a licensing agreement. At their request, the company’s identity and the detailed agreement will remain confidential until a definitive agreement is executed.
Sirona has received an up-front payment for the acceptance of the ROFR.
“We are very pleased to have established this arrangement. A great deal of time and resources have been invested by both Sirona and the skincare company working on the advancement of TFC-1067 with the goal of an international commercial launch”, reports Dr. Howard Verrico, CEO of Sirona. “In order to protect the company and justify their ongoing efforts, the ROFR was a necessary step in advance of our clinical trial results, as these results are also greatly anticipated by other major skincare companies. This is an exciting time for Sirona’s team here in Canada as well as our scientific team in France and marks another milestone towards commercially launching a disruptive new skin lightening ingredient in this 20 Billion USD global skin lightening market1.”
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
1 |
Fact.MR (July 2018) Retrieved from: https://globenewswire.com/news-release/2018/07/10/1535161/0/en/Key-Insights-on-Skin-Lightening-Products-Market-through-2022-by-Fact-MR.html |
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2019/06/c8940.html
Contact:
regarding this press release, please contact: Christopher Hopton, CFO, Sirona Biochem Corp., Phone: 1.604.282.6064, Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
CROP’s Nevada Farm Final Inspection is Done With Licenses Expected to be Issued Shortly
Momentum Public Relations
Press Release: February 05, 2019
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today final inspection has been completed at its THC cultivation, production, commercial kitchen and extraction facility in Nevada. The final medical and recreational licenses are expected to be granted later this month.
Meanwhile, construction continues there on the 40-acre perimeter wall for outdoor and greenhouse production. The 40-acre outdoor project is expected to cost $500,000 and is forecast to yield 80,000 pounds of high quality, organically grown outdoor cannabis which will be mostly for sale to extractors and for the company’s tenant extraction quotas. The project is now 50% paid for.
The company is now accepting off take and supply agreements requests for 2019 harvest.
CROP CEO, Michael Yorke, stated: “With our ultra low cost, organic outdoor focus in Nevada, our tenant farms will provide extractors with cost effective extraction materials giving both CROP and our tenants a significant competitive advantage in Nevada for the 2019 season and beyond.”
About CROP
Crop is publicly listed on the CSE and trades under the symbol “CROP”. CROP is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, U.S. and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Nevada Project; the technological effects of Nevada Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604)484-4206
View original content:http://www.prnewswire.com/news-releases/crops-nevada-farm-final-inspection-is-done-with-licenses-expected-to-be-issued-shortly-300789827.html
- Published in Business, CROP Infrastructure, Marijuana, News Home
CROP Farm to Produce 50 L of THC Oil and Applies for Chula Vista Dispensary Location
Momentum Public Relations
Press Release: January 24, 2019
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it will, initially, be making 100,000 premium Moon Rock Cones at one of its California subsidiaries as it expands its footprint in the state.
The raw material will be finished cannabis from CROP’s Humboldt County farm which is trimmed, high grade flower and will be for distillate input for cartridges and pre-rolls cones that will then be dipped in kief (cannabis crystals) to make the infused cones. The infused cones will be Hempire and Evolution branded with custom filters bearing the name. Additional equipment to fulfill the order is expected to arrive shortly.
After some initial market research, the company has established the best-selling SKUS are cones and pens. The company has instructed its toll process partner to convert equivalent material to produce approximately 50 liters of oil to fill 75,000 half gram cartridges and 50,000 quarter gram disposable pens, as well as the company will roll and tube approximately 200,000 Hempire and evolution branded 1-gram infused cones.
The distributor has offices in Oakland and Orange County. The distribution network consists of approximately 350 licensed cannabis stores across California.
The farm will shortly be taking down an additional 10,000 sq. ft. of canopy crop for harvest. Additionally, the company has retained local engineers to plan and permit the 2019 expansion, including a proposed 30,000 sq. ft. automated greenhouse facility, extra vault space and security upgrades.
CROP also announced it has made a cannabis retail application in Chula Vista, California, for its Emerald Height’s brand and is working with its local partners to apply in additional municipalities.
CROP CEO, Michael Yorke, stated: “Having wide distribution of a premium organic Infused Cone with over 100,000 branded units and 125,000 pen cartridges set to be consumed in California, this is a major step forward for our brand portfolio and tenant farm.”
About CROP
CROP is publicly listed on the CSE and trades under the symbol “CROP”. CROP is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the California Project; the technological effects of California Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact:
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: http://www.cropcorp.com
Phone: +1(604)484-4206
SOURCE Crop Infrastructure Corp.
- Published in Business, CROP Infrastructure, hemp, Marijuana, Medical Marijuana, News Home